Oncotelic Therapeutics Highlights Robust Oncology Pipeline and CEO's Extensive Patent Portfolio

Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical stage biopharmaceutical company, has highlighted its comprehensive oncology pipeline and the significant intellectual property legacy of Chairman and CEO Dr. Vuong Trieu, who holds more than 500 filed and 75 issued patents. The company's portfolio includes multiple advanced therapeutic candidates, with OT-101 currently in Phase 3 development for pancreatic cancer treatment. This positioning reflects the company's strategic focus on addressing critical unmet medical needs in oncology through innovative approaches.

The pipeline further includes OXi4503 advancing toward Phase 3 trials for acute myeloid leukemia and myelodysplastic syndromes, demonstrating the company's commitment to hematologic malignancies. Additionally, CA4P/Fosbretabulin is undergoing late-stage repositioning, potentially expanding its therapeutic applications beyond initial indications. The diversity of the pipeline extends beyond oncology, with AL-101 in Phase 2 development for Parkinson's disease and sexual dysfunctions, while AL-102 remains in discovery phase targeting Alzheimer's disease.

Notably, Oncotelic maintains multiple pediatric rare disease programs that carry the potential to generate Priority Review Vouchers, which could significantly accelerate regulatory review processes for future drug candidates. This strategic approach reinforces the company's methodology of building value through differentiated biotechnology assets with strong competitive barriers. The company's mission focuses specifically on developing oncology and immunotherapy products that address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

Beyond its directly owned and developed drug pipeline, Oncotelic benefits from the extensive portfolio of inventions created by Dr. Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. The company also engages in licensing and co-development activities through joint ventures, currently owning 45% of GMP Bio, a joint venture under Dr. Trieu's leadership that is advancing its own pipeline of drug candidates. This multifaceted approach strengthens Oncotelic's strategic position in both oncology and rare disease therapeutics, creating multiple value drivers for the company's future development. For additional information about the company's programs and pipeline, visit https://www.oncotelic.com/.